Abstract：Acute myeloid leukemia (AML) is a rare type of childhood acute leukemia, which has a worse prognosis than childhood acute lymphoblastic leukemia. Over the past decade, significant progress has been made in the treatment of childhood AML and the 5-year event-free survival rate may be as high as 70% in developed countries. This survival improvement is largely attributable to risk-stratified treatments, therapies tailored to individual patients based on the biological characteristics of the disease, and continuously improving supportive care. An accurate diagnosis is the prerequisite for risk stratification, prognostic evaluation and therapeutic decision making. How to reduce early mortality and thus improve overall survival, how to implement appropriate supportive treatment to reduce treatment-associated complications, and how to reduce treatment-related mortality are the key to the improvement of therapies for childhood acute myeloid leukemia.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel[J]. Blood, 2012, 120(16): 3187-3205.
Zhang L, Zhu X. Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in China[J]. Mediterr J Hematol Infect Dis, 2012, 4(1): e2012012.
[5]
Zhang L, Zhu X, Zou Y, et al. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China[J]. Int J Hematol, 2011, 93(2): 199-205.
[6]
Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia[J]. Blood, 2010, 115(9): 1697-702.
[7]
Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome[J]. Crit Rev Oncog, 2011, 16(1-2): 25-36.
[8]
Creutzig U, Zimmermann M, Bourquin JP, et al. Favorable outcome in infants with AML after intensive first-and second-line treatment: an AML-BFM study group report[J]. Leukemia, 2012, 26(4): 654-661.
[9]
Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group[J]. Blood, 2013, 121(18): 3573-3577.
